Designing molecular diagnostics for current tuberculosis drug regimens
Diagnostic development must occur in parallel with drug development to ensure the
longevity of new treatment compounds. Despite an increasing number of novel and …
longevity of new treatment compounds. Despite an increasing number of novel and …
Rapid Diagnosis of Drug-Resistant Tuberculosis–Opportunities and Challenges
Global tuberculosis (TB) eradication is undermined by increasing prevalence of emerging
resistance to available drugs, fuelling ongoing demand for more complex diagnostic and …
resistance to available drugs, fuelling ongoing demand for more complex diagnostic and …
Advances in molecular diagnosis of tuberculosis
Molecular tests for tuberculosis (TB) have the potential to help reach the three million people
with TB who are undiagnosed or not reported each year and to improve the quality of care …
with TB who are undiagnosed or not reported each year and to improve the quality of care …
Application of next generation sequencing for diagnosis and clinical management of drug-resistant tuberculosis: updates on recent developments in the field
N Dookie, A Khan, N Padayatchi, K Naidoo - Frontiers in Microbiology, 2022 - frontiersin.org
The World Health Organization's End TB Strategy prioritizes universal access to an early
diagnosis and comprehensive drug susceptibility testing (DST) for all individuals with …
diagnosis and comprehensive drug susceptibility testing (DST) for all individuals with …
[图书][B] Use of targeted next-generation sequencing to detect drug-resistant tuberculosis: rapid communication, July 2023
World Health Organization - 2023 - books.google.com
Background In 2021, more than 10 million people fell ill with tuberculosis (TB), including
almost half a million with multi-drug or rifampicin-resistant TB (MDR/RR-TB)(1). Only one …
almost half a million with multi-drug or rifampicin-resistant TB (MDR/RR-TB)(1). Only one …
[HTML][HTML] Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon
Tuberculosis is an ever evolving infectious disease that still claims about 1.8 million human
lives each year around the globe. Although modern chemotherapy has played a pivotal role …
lives each year around the globe. Although modern chemotherapy has played a pivotal role …
Screening approaches and therapeutic targets: The two driving wheels of tuberculosis drug discovery
Tuberculosis (TB) is an infectious disease, infecting a quarter of world's population. Drug
resistant TB further exacerbates the grim scenario of the drying TB drug discovery pipeline …
resistant TB further exacerbates the grim scenario of the drying TB drug discovery pipeline …
Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene …
CRyPTIC Consortium, JJ Carter - bioRxiv, 2021 - biorxiv.org
Abstract The World Health Organization goal of universal drug susceptibility testing for
patients with tuberculosis is most likely to be achieved through molecular diagnostics; …
patients with tuberculosis is most likely to be achieved through molecular diagnostics; …
Advances in diagnostics and drug discovery against resistant and latent tuberculosis infection
C Shleider Carnero Canales, J Marquez Cazorla… - Pharmaceutics, 2023 - mdpi.com
Latent tuberculosis infection (LTBI) represents a subclinical, asymptomatic mycobacterial
state affecting approximately 25% of the global population. The substantial prevalence of …
state affecting approximately 25% of the global population. The substantial prevalence of …
Tuberculosis drug discovery in the post‐post‐genomic era
B Lechartier, J Rybniker, A Zumla… - EMBO molecular …, 2014 - embopress.org
The expectation that genomics would result in new therapeutic interventions for infectious
diseases remains unfulfilled. In the post‐genomic era, the decade immediately following the …
diseases remains unfulfilled. In the post‐genomic era, the decade immediately following the …